drugset / Trial / NCT04448457

Sufentanil Sublingual Tablet System for Postoperative Pain Management After Total Knee Arthroplasty

NCT04448457

RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study is to assess the effectiveness of Sublingual Sufentanil Tablets System (SSTS, Zalviso ®) to control postoperative pain after total knee arthroplasty in the context of early rehabilitation program. SSTS is a novel patient controlled analgesia system wich does not require intravenous access, potentially improving pain control and promoting mobilization. SSTS will be randomly compared to nurse-driven oral Oxycodone.

Timeline

Start
2017-09-01
Primary completion
2018-07-31
Completion
2018-07-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Oxycodone Other / unclassified 5 mg Oral
Comparator Oxycodone Other / unclassified 10 mg Oral
Subject Sufentanil Other / unclassified 15 ug Other

Indications

No indication recorded.